In contrast, single agent TKIs is less effective in tumors that amplify and over-express RTKs such as the EGFR family (HER1 in head and neck cancer, HER2 in breast cancer, HER1 and 2 in pancreas cancer). This evidence concerns the gene ERBB2 and breast carcinoma.